vs
AMN HEALTHCARE SERVICES INC（AMN）与亚什兰（ASH）财务数据对比。点击上方公司名可切换其他公司
AMN HEALTHCARE SERVICES INC的季度营收约是亚什兰的1.9倍（$748.2M vs $386.0M），AMN HEALTHCARE SERVICES INC净利率更高（-1.0% vs -3.1%，领先2.1%），AMN HEALTHCARE SERVICES INC同比增速更快（1.8% vs -4.7%），亚什兰自由现金流更多（$111.0M vs $67.6M），过去两年AMN HEALTHCARE SERVICES INC的营收复合增速更高（-4.5% vs -18.1%）
AMN医疗保健服务公司是美国领先的医疗人力资源解决方案提供商，主要为医院、诊所等各类医疗机构提供护士、医师、医技人员及其他临床、非临床岗位的临时与长期派遣服务，同时提供医护团队管理技术支持及相关咨询服务。
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
AMN vs ASH — 直观对比
营收规模更大
AMN
是对方的1.9倍
$386.0M
营收增速更快
AMN
高出6.5%
-4.7%
净利率更高
AMN
高出2.1%
-3.1%
自由现金流更多
ASH
多$43.4M
$67.6M
两年增速更快
AMN
近两年复合增速
-18.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $748.2M | $386.0M |
| 净利润 | $-7.7M | $-12.0M |
| 毛利率 | 26.1% | 27.2% |
| 营业利润率 | 1.1% | -1.6% |
| 净利率 | -1.0% | -3.1% |
| 营收同比 | 1.8% | -4.7% |
| 净利润同比 | 95.9% | 92.7% |
| 每股收益（稀释后） | $-0.19 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMNASH
| Q4 25 | $748.2M | $386.0M | ||
| Q3 25 | $634.5M | $477.0M | ||
| Q2 25 | $658.2M | $463.0M | ||
| Q1 25 | $689.5M | $479.0M | ||
| Q4 24 | $734.7M | $405.0M | ||
| Q3 24 | $687.5M | $521.0M | ||
| Q2 24 | $740.7M | $544.0M | ||
| Q1 24 | $820.9M | $575.0M |
净利润AMNASH
| Q4 25 | $-7.7M | $-12.0M | ||
| Q3 25 | $29.3M | $31.0M | ||
| Q2 25 | $-116.2M | $-742.0M | ||
| Q1 25 | $-1.1M | $31.0M | ||
| Q4 24 | $-187.5M | $-165.0M | ||
| Q3 24 | $7.0M | $17.0M | ||
| Q2 24 | $16.2M | $6.0M | ||
| Q1 24 | $17.3M | $120.0M |
毛利率AMNASH
| Q4 25 | 26.1% | 27.2% | ||
| Q3 25 | 29.1% | 33.3% | ||
| Q2 25 | 29.8% | 28.5% | ||
| Q1 25 | 28.7% | 30.7% | ||
| Q4 24 | 29.8% | 27.4% | ||
| Q3 24 | 31.0% | 33.2% | ||
| Q2 24 | 31.0% | 34.2% | ||
| Q1 24 | 31.4% | 28.0% |
营业利润率AMNASH
| Q4 25 | 1.1% | -1.6% | ||
| Q3 25 | 7.5% | 12.8% | ||
| Q2 25 | -18.8% | -152.9% | ||
| Q1 25 | 1.8% | 10.6% | ||
| Q4 24 | -27.6% | -44.2% | ||
| Q3 24 | 3.2% | 6.1% | ||
| Q2 24 | 5.1% | -11.2% | ||
| Q1 24 | 4.9% | 3.7% |
净利率AMNASH
| Q4 25 | -1.0% | -3.1% | ||
| Q3 25 | 4.6% | 6.5% | ||
| Q2 25 | -17.7% | -160.3% | ||
| Q1 25 | -0.2% | 6.5% | ||
| Q4 24 | -25.5% | -40.7% | ||
| Q3 24 | 1.0% | 3.3% | ||
| Q2 24 | 2.2% | 1.1% | ||
| Q1 24 | 2.1% | 20.9% |
每股收益（稀释后）AMNASH
| Q4 25 | $-0.19 | $-0.26 | ||
| Q3 25 | $0.76 | $0.83 | ||
| Q2 25 | $-3.02 | $-16.21 | ||
| Q1 25 | $-0.03 | $0.65 | ||
| Q4 24 | $-4.90 | $-3.50 | ||
| Q3 24 | $0.18 | $0.34 | ||
| Q2 24 | $0.42 | $0.12 | ||
| Q1 24 | $0.45 | $2.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.0M | $304.0M |
| 总债务越低越好 | $767.1M | $1.4B |
| 股东权益账面价值 | $642.1M | $1.9B |
| 总资产 | $2.1B | $4.5B |
| 负债/权益比越低杠杆越低 | 1.19× | 0.74× |
8季度趋势，按日历期对齐
现金及短期投资AMNASH
| Q4 25 | $34.0M | $304.0M | ||
| Q3 25 | $52.6M | $215.0M | ||
| Q2 25 | $41.5M | $207.0M | ||
| Q1 25 | $55.8M | $168.0M | ||
| Q4 24 | $10.6M | $219.0M | ||
| Q3 24 | $30.6M | $300.0M | ||
| Q2 24 | $48.0M | $399.0M | ||
| Q1 24 | $50.6M | $439.0M |
总债务AMNASH
| Q4 25 | $767.1M | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | $1.1B | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.3B |
股东权益AMNASH
| Q4 25 | $642.1M | $1.9B | ||
| Q3 25 | $644.4M | $1.9B | ||
| Q2 25 | $607.6M | $1.9B | ||
| Q1 25 | $715.1M | $2.6B | ||
| Q4 24 | $706.6M | $2.6B | ||
| Q3 24 | $890.7M | $2.9B | ||
| Q2 24 | $876.9M | $3.0B | ||
| Q1 24 | $854.2M | $3.1B |
总资产AMNASH
| Q4 25 | $2.1B | $4.5B | ||
| Q3 25 | $2.1B | $4.6B | ||
| Q2 25 | $2.2B | $4.6B | ||
| Q1 25 | $2.4B | $5.2B | ||
| Q4 24 | $2.4B | $5.2B | ||
| Q3 24 | $2.7B | $5.6B | ||
| Q2 24 | $2.8B | $5.7B | ||
| Q1 24 | $2.9B | $5.9B |
负债/权益比AMNASH
| Q4 25 | 1.19× | 0.74× | ||
| Q3 25 | — | 0.73× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 0.52× | ||
| Q4 24 | 1.49× | 0.51× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 0.45× | ||
| Q1 24 | — | 0.42× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.6M | $125.0M |
| 自由现金流经营现金流 - 资本支出 | $67.6M | $111.0M |
| 自由现金流率自由现金流/营收 | 9.0% | 28.8% |
| 资本支出强度资本支出/营收 | 1.1% | 3.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $233.8M | $200.0M |
8季度趋势，按日历期对齐
经营现金流AMNASH
| Q4 25 | $75.6M | $125.0M | ||
| Q3 25 | $22.7M | $40.0M | ||
| Q2 25 | $78.5M | $115.0M | ||
| Q1 25 | $92.7M | $9.0M | ||
| Q4 24 | $72.8M | $-30.0M | ||
| Q3 24 | $66.7M | $80.0M | ||
| Q2 24 | $99.5M | $127.0M | ||
| Q1 24 | $81.4M | $54.0M |
自由现金流AMNASH
| Q4 25 | $67.6M | $111.0M | ||
| Q3 25 | $14.8M | $6.0M | ||
| Q2 25 | $68.7M | $95.0M | ||
| Q1 25 | $82.7M | $-12.0M | ||
| Q4 24 | $56.6M | $-53.0M | ||
| Q3 24 | $47.4M | $42.0M | ||
| Q2 24 | $72.2M | $98.0M | ||
| Q1 24 | $63.2M | $20.0M |
自由现金流率AMNASH
| Q4 25 | 9.0% | 28.8% | ||
| Q3 25 | 2.3% | 1.3% | ||
| Q2 25 | 10.4% | 20.5% | ||
| Q1 25 | 12.0% | -2.5% | ||
| Q4 24 | 7.7% | -13.1% | ||
| Q3 24 | 6.9% | 8.1% | ||
| Q2 24 | 9.8% | 18.0% | ||
| Q1 24 | 7.7% | 3.5% |
资本支出强度AMNASH
| Q4 25 | 1.1% | 3.6% | ||
| Q3 25 | 1.2% | 7.1% | ||
| Q2 25 | 1.5% | 4.3% | ||
| Q1 25 | 1.4% | 4.4% | ||
| Q4 24 | 2.2% | 5.7% | ||
| Q3 24 | 2.8% | 7.3% | ||
| Q2 24 | 3.7% | 5.3% | ||
| Q1 24 | 2.2% | 5.9% |
现金转化率AMNASH
| Q4 25 | — | — | ||
| Q3 25 | 0.77× | 1.29× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | — | ||
| Q3 24 | 9.54× | 4.71× | ||
| Q2 24 | 6.13× | 21.17× | ||
| Q1 24 | 4.70× | 0.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMN
| Travel Nurse Staffing | $208.3M | 28% |
| Allied Staffing | $146.9M | 20% |
| Labor Disruption Services | $124.3M | 17% |
| Technology And Workforce Solutions | $88.0M | 12% |
| Language Services | $69.9M | 9% |
| Other | $29.6M | 4% |
| International Nurse Staffing | $29.6M | 4% |
| Interim Leadership Staffing | $24.1M | 3% |
| Vendor Management Systems | $16.3M | 2% |
| Local Staffing | $8.6M | 1% |
| International Nurse Permanent Placement | $2.6M | 0% |
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
